PT-2385

• Description :

  PT-2385 is a selective HIF-2α inhibitor with a Ki of less than 50 nM[1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  HIF/HIF Prolyl-Hydroxylase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/PT-2385.html

• Purity :

  99.95

• Solubility :

  DMSO : ≥ 50 mg/mL

• Smiles :

  N#CC1=CC(F)=CC(OC2=CC=C(S(=O)(C)=O)C3=C2CC(F)(F)[C@H]3O)=C1

• Molecular Formula :

  C17H12F3NO4S

• Molecular Weight :

  383.34

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Eli Wallace, Ph.D. PT2385: HIF-2α Antagonist for the Treatment of VHL Mutant ccRCC. 12th International VHL Medical Symposium April 8, 2016.|[2]Xie C, et al. Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis. Nat Med. 2017 Nov;23 (11) :1298-1308.|[3]Wallace EM, et al. A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma. Cancer Res. 2016 Sep 15;76 (18) :5491-500.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• CAS Number :

  [1672665-49-4]